



THE PROBLEM



Colorectal cancer (CRC) is the second most incident cancer and mortal worldwide. **Colonoscopy**, the gold standard for CRC diagnosis, is **expensive** and **hazardous**. Existing **non-invasive** tools for CRC screening as the fecal immunochemical test (FIT) have **low sensitivity** and **reduced predictability**. There is a **need** for a **new CRC screening tool**.

 **1,8M** new cases of **CRC** 2018

 **30%** unnecessary colonoscopies from FIT false positives

 **1/1000** Colonoscopy Risk of death

 **2.000 – 2.500€** / colonoscopy

THE SOLUTION



RAID-CRC is the first non-invasive technology for CRC screening based on detecting a specific bacterial signature in the fecal sample.

- This non-invasive tool allows reliable and fast CRC early detection, increasing sensitivity for precancerous lesions to 59% and reducing up to 32% unnecessary colonoscopies.
- Uses the same FIT collector.

KEY BENEFITS




-  **SAFER: Higher sensitivity (98%) and false positive reduction (61%)**
-  **FASTER: CRC detection in 2h**
-  **CHEAPER: <50€ / test**
-  **EASIER: Easiness of implantation** in the current healthcare workflows.


MILESTONES

- 2014 **Foundation**
- 2015 **Proof of Concept**
- 2016 **Analytic Validation**
- 2017 **Patent Protection**
- 2018 **Clinical Validation**
- 2019 – 2020 **CE Mark**
- 2020 – 2021 **Market Launch**

FUNDS RAISED



FUNDING GOALS



 **WA4STEAM** Lead investor
Women Angels for STEAM

KEYMETRICS

- <50€** Price / test
- 6M€** Current valuation
- 80%** Potential penetration rate
- 81,3 bn\$** Global in vitro diagnostics market
- 37% TIR** (Exit 2021 M&A)

MANAGING TEAM



Mariona Serra
CEO




Xavier Aldeguer
Medical Director




Jesús Garcia-Gil
CRO




Jaume Amat
Strategic Advisor
